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Abstract
Background: Chronic heart failure (CHF) has a high morbidity and mortality. Chronic kidney
disease (CKD) has consistently been found to be an independent risk factor for unfavorable
cardiovascular (CV) outcomes. Early intervention on CKD reduces the progression of CHF,
hospitalizations and mortality, yet there are very few studies about CKD as a risk factor in the early
stages of CHF. The aims of our study were to assess the prevalence and the prognostic importance
of CKD in patients with systolic CHF stages B and C.
Methods: This is a prospective cohort study, dealing with prognostic markers for CV endpoints
in patients with systolic CHF (ejection fraction  45%).
Results: CKD was defined as estimated glomerular filtration rate <60 mL/min/1.73 m2 and CV
endpoints as death or hospitalization due to CHF, in 12 months follow-up. Eighty three patients
were studied, the mean age was 62.7 ± 12 years, and 56.6% were female. CKD was diagnosed in
49.4% of the patients, 33% of patients with CHF stage B and 67% in the stage C. Cardiovascular
endpoints were observed in 26.5% of the patients. When the sample was stratified into stages B
and C of CHF, the occurrence of CKD was associated with 100% and 64.7%, respectively, of
unfavorable CV outcomes. After adjustments for all other prognostic factors at baseline, it was
observed that the diagnosis of CKD increased in 3.6 times the possibility of CV outcomes (CI 95%
1.04-12.67, p = 0.04), whereas higher ejection fraction (R = 0.925, IC 95% 0.862-0.942, p = 0.03)
and serum sodium (R = 0.807, IC 95% 0.862-0.992, p = 0.03) were protective.
Conclusion: In this cohort of patients with CHF stages B and C, CKD was prevalent and
independently associated with increased risk of hospitalization and death secondary to cardiac
decompensation, especially in asymptomatic patients.
Background
Chronic heart failure (CHF) is considered a public health
problem, in view of its high costs and increasing number
of hospital admissions [1-4]. In Brazil, the public health
system, Sistema Único de Saúde (SUS), is responsible for
more than 75% of the hospitalization for CHF, which
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implementation in recent years of effective strategies to
reduce the mortality of patients with CHF, the mortality
rates resulting from the disease still remain high, and are
directly related to the duration and frequency of hospital-
ization [1,2,5-7]. Similar to the presence of symptoms in
heart failure, the presence of hospitalization secondary to
CHF decompensation, per se, predicts cardiovascular mor-
tality [7-9].
Chronic kidney disease (CKD) is associated with a high
risk of cardiovascular events [10-12]. It is an independent
risk factor for adverse outcomes, recurrence of hospitaliza-
tion, and in comparison with the general population,
increases by 15 to 30 times cardiovascular (CV) mortality
[12,13]. In fact, death mainly due to CV causes is far more
common than dialysis at all stages of CKD [14].
The prevalence of CHF among CKD patients is elevated
and equally predicts mortality [13-16]. CHF is a common
cause of renal impairment, and its decompensation is a
major cause of CKD progression [15]. On the other hand,
reduced glomerular filtration (GF) linearly associates with
increased prevalence of CHF [15,17].
Most studies which assess the negative impact of CKD and
other factors in the curse of CHF have been done in
patients with most severe form of the disease (NYHA
Class IV of CHF), usually in a hospital setting [4,8,14-
16,18]. Recently, CHF patients with asymptomatic systo-
lic dysfunction were evaluated, and the presence of CKD
was associated with a greater mortality [17].
Despite the incentives, the prognostic classification of
CHF has rarely been applied in practice. This may be one
of the explanations for the scarcity of studies evaluating
risk factors and adverse outcomes in outpatients with CHF
[1-3]. In the present study, we aimed to investigate the
prevalence of CKD and its possible association with cardi-




Eighty-three patients treated at the Center for Control of
Hypertension, Diabetes and Obesity - SCHDO, in the city
of Juiz de Fora- MG, were observed from the period of Jan-
uary through December of 2006.
SCHDO is a municipal unit of secondary outpatient clinic
that offers free treatment to hypertensive patients in stage
3, group C, complications of type 2 diabetics, type 1 dia-
betics with difficult clinical control, 3rd degree obese
patients with associated morbidities, and those referred
from other municipal basic health care units.
This was an observational study during which the patients
were prospectively followed for 12 months, for surveil-
lance of cardiovascular outcomes. Data were collected at
the study baseline and after 12 months. All patients con-
firmed participation by signing the informed consent
form, and the study was approved by the Ethics Commit-
tee of the Federal University of Juiz de Fora.
The patients were selected among those with CHF who
were attended bimonthly at the SCHDO. The patients
were taking medications that optimize CHF treatment,
including angiotensin-converting enzyme inhibitors and/
or angiotensin receptor blocker, beta-blocker (carvedilol),
furosemide, and digital when indicated. Patients over the
age of 18 years, regularly attending the Clinic in the last six
months, with CHF stages B and C, and ejection fraction by
bi-dimensional Doppler echocardiogram of less than or
equal to 45% were included [2]. Patients with active infec-
tious-contagious diseases, neoplasia, and systolic CHF
possibly reverted, such as valvular or coronary lesions
with indication for percutaneous or surgical correction,
were excluded from the study.
The patients were classified according to the chronological
staging of CHF, in stages B and C. Stage B was character-
ized when there was a structural heart disease and no
symptoms (NYHA class I symptoms), and stage C when
the structural disease was associated with previous or cur-
rent symptoms (NYHA class II or III symptoms) [1,3].
Demographic data, such as age and sex, were evaluated, as
well as cardiovascular risk factors. Obesity was diagnosed
when the body mass index (BMI) was greater than 30 kg/
m2; sedentariness was considered when the regular physi-
cal activity was less than 30 minutes per day and less than
3 times per week; smokers were identified as those who
smoke at least one cigarette per day for a period of more
than six months; arterial hypertension was considered
when blood pressure levels were above 140 × 90 mmHg,
or when on antihypertensive treatment; diabetes mellitus
was diagnoses when the fasting blood glucose levels were
over 100 mg/dL, or when using an oral hypoglycemic
medication or insulin [19-22].
The diagnosis of ischemic cardiopathy (IC) was based on
previous history and/or documented upon hospitaliza-
tion by angina, acute myocardial infarction, myocardial
revascularization, percutaneous transcoronary angi-
oplasty, or coronary angiography with injuries consistent
with coronary artery disease [23]. Pulse pressure (PP) was
considered abnormal when values were equal or higher
than 53 mmHg [24]. Laboratory parameters and respec-
tive cut-offs for normality (in brackets) were: serum
hemoglobin (>12 g/dL), fasting blood glucose (<100 mg/
dL), total cholesterol (<200 mg/dL), LDL-cholesterolPage 2 of 7
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sodium (140 a 148 mEq/L) [20,25].
The echocardiographic parameters studied were left ven-
tricular ejection fraction (including those patients with
percentage  45%), measures of left atrium diameter, and
of left ventricular diastolic diameter, due to their impor-
tance as prognostic parameters in CHF [1,3].
The glomerular filtration rate (GFR) was estimated by the
determination of serum creatinine using the equation of
the study Modification of Diet in Renal Disease (MDRD)
[26]. The diagnosis and stage of the CKD were made
according to the criteria of the US National Kidney Foun-
dation [27]. Patients with two results of GFR <60 mL/
min/1.73 m2, measured at least 3 months apart, were
diagnosed with CKD [27]. The outcomes were cardiovas-
cular death or hospitalization secondary to decompen-
sated CHF, during the 12 months of follow up.
The Kolmogorov-Smirnov study was used for evaluation
of the presence or not of normal distribution of the varia-
bles. The data were expressed as mean and standard devi-
ation and percentages. The population was divided into
stages B and C of CHF. To compare the qualitative varia-
bles among the two groups, we utilized the chi-squared
test or the Fisher's test, and for numerical variables the
Student's t test or the Mann-Whitney test.
The univariate analysis was used to evaluate the associa-
tion between the stages of CHF and the occurrence of out-
comes. The multivariate analysis was employed by the
backward logistic regression method in order to evaluate
the relationship between outcomes, stages of CHF, and
the covariates that presented p-valor  0.1 in the univari-
ate analysis. In the first stage of regression, we utilized var-
iables for which the p-value in the univariate analysis was
less that 0.1. The level of significance was set at 5%. The
analyses were performed using the SPSS program for Win-
dows 11.0 (SPSS Inc, Chicago, IL).
Results
There were 87 eligible patients, of which 83 met the inclu-
sion criteria, 33 (39.8%) in stage B of CHF, and 50
(60.2%) in stage C. The mean age of the patients was 62.6
± 12 years, and 47 were (56.6%) females. Sedentarism
and smoking were presented in 57 (68.7%) and 12
(14.5%) patients, respectively. Of the total patients, 79
(95.2%) were hypertensive, and 41 (49.4%) were type 2
diabetics. Stage C was diagnosed in 50 (60.2%) of the
patients, representing the major cause of CHF. With the
exception of sedentarism, more frequent in patients with
CHF stage C compared to stage B (p = 0.02), there were no
statistical differences in the remaining demographic
parameters between the two groups. (Table 1) The mean
BMI was 30.3 ± 7.8 kg/m2, and 33 patients (39.8%) were
obese. The mean systolic blood pressures were 134.5 ±
20.3 mmHg and the mean PP was 52.2 ± 16.2 mmHg. The
mean values of hemoglobin, blood glucose, total choles-
terol, LDL-cholesterol, and triglycerides, were not differ-
ent after stratification of patients in stages B and C of CHF
(Table 1).
The measurement of left atrium, left ventricular diastolic
diameter, and ejection fraction on the echocardiogram
were 43.1 ± 7.8 mm, 63.5 ± 12.6 mm and 37.8 ± 7.9%,
respectively, and did not reach statistical differences after
CHF staging (Table 1).
The evaluation of the renal function by creatinine and
GFR did not differ statistically between the two stages of
CHF. CKD (GFR <60 mL/min/1.73 m2) was diagnosed in
41 (49.4%) patients, 14 (42.4%) in the stage B of CHF
and 27 (54%) in the stage C (p = 0.05) (Table 1). The
absolute majority of patients (85.4%) presented GFR
between 30-59 ml/min/17.3 m2 (stage 3 of CKD).
The stratification of patients according to occurrence or
not of CKD and stages of CHF did not present evidence of
differences among demographic characteristics, physical
exam, laboratory parameters, or baseline echocardiogram
findings, with the exception of an elevated serum creati-
nine in patients with CHF and CKD (p = 0.02) (Table 2).
The figure 1 presents the cardiovascular outcomes related
to the presence or not of CKD in the group as whole, and
after stratification by stage. In general, the concurrence of
CKD imposes a worse prognosis in patients with CHF. CV
outcomes were observed in 22 (26.5%) patients, of which
17 (77.2%) presented CKD. The separation by stages of
CHF showed that the presence of CKD was associated
with CV outcomes in 5 (100%) patients in the stage B (p
= 0.005) and in 8 (64.7%) in the stage C (p = 0.05).
Table 3 presents the univariate and multivariate analyses
with Cox's regression model for the clinical prognostic
factors determining unfavorable CV outcomes. The uni-
variate analysis showed that sedentarism (RR 3.83; CI95%
1.021-14395; p = 0.04), stage C of CHF (RR 2.885; CI95%
0.944-8.816, p = 0.06), increased LDL-cholesterol (RR
0.354; CI 95% 0.120-1.044; p = 0.06), serum sodium (RR
0.825; CI95% 0.694-0.981; p = 0.02), left ventricular ejec-
tion fraction (RR 0.910; CI95% 0.854-0.970; p = 0.004),
and CKD (RR 2.891; CI95% 1.052-7.949; p = 0.04) were
significantly associated with CV outcomes. The multivari-
ate regression analysis for clinically relevant prognostic
factors identified in the univariate analysis showed that
the presence of CKD, independently, increased by 3.6
times the chances of occurrence of CV events (CI 95%
1.04-12.67; p = 0.04), while elevated levels of serumPage 3 of 7
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ejection fraction (RR 0.925; CI 95% 0.862-0.942; p =
0.03) showed to be protective.
Discussion
Our study demonstrated that in the cohort of patients
studied, CKD was highly prevalent in stages B and C of
CHF, and significantly associated with a greater occur-
rence of death and hospitalization due to cardiac causes.
The unfavorable impact of concomitant occurrence of
CKD and CHF was observed in stages B and C of cardiac
disease. These findings complement previous observa-
tions in patients with more severe forms of CHF (NYHA
class IV), that CKD is a frequent complication with an
unfavorable impact in the course of the disease
[9,11,15,17,19,23,28,29].
Estimation of the GFR used to define glomerular filtration
rate (GFR) and CKD stages according to the criteria of the
US National Kidney Foundation is considered the new
standard of evaluation and severity of renal diseases
[12,27]. So far, the utility of this system of staging based
on the GFR as a risk factor for prediction of adverse out-
come has not been extensively evaluated in patients in less
advanced stages of CHF [16,28]. The cohort studied, after
adjustment of other important risk factors for unfavorable
CV outcomes presented at the baseline period, demon-
strated that the occurrence of CKD independently deter-
mined a greater occurrence of mortality and
hospitalization, an observation still little explored in out-
patients with CHF.
The greater occurrence of CV outcomes in patients with
CHF and CKD can be explained by the overlap of risk fac-
tors common in both diseases separately [30-32]. Previ-
ous studies, limited to analyses of databases and
stratification of patients into levels of renal function based
on dichotomous divisions or tertiles, have demonstrated
an association between increased mortality and renal
function in patients with CHF [33]. Our findings of CKD
as an independent risk factor for CV outcomes is in
accordance with other large cohort studies based on com-
munities and other populations with cardiovascular dis-
eases [6,8,12,13,15,16,18,34,35].
The natural course of CHF in its initial stages associated
with CKD is still unknown, since, thus far, most studies
have evaluated primarily hospitalized patients with severe
form of the disease (NYHA class IV), mainly in cross-sec-
tional analyses, and improperly using serum creatinine as
Table 1: Baseline characteristics of patients with CHF, stratified in stages B and C.
Total patients with CHF
Variables Total population Stage B Stage C P
N 83 39.8% (33/83) 60.2% (50/83)
Age (years) 62.7 ± 12.1 60.4 ± 11.8 64.2 ± 12.2 0.16
Females (47) 56.6% (17) 55.4% (30) 63.8% 0.44
Arterial hypertension (79) 95.2% (31) 93.9% (48) 96% 0.66
Type 2 diabetes mellitus (41) 49.4%% (18) 54.5% (23) 46% 0.44
Sedentarism (57) 68.7% (18) 54.5% (39) 78% 0.02
Smoking (12) 14.5% (6) 18.2% (6) 2% 0.31
Ischemic Cardiopathy (50) 60.2% (23) 69.7% (27) 54% 0.15
BMI 30,3 ± 7,8 28.7 ± 6.2 31.3 ± 8.7 0.12
Obesity (33) 39,8% (10) 30.3% (23) 46% 0.11
SBP 134.5 ± 20.3 131.8 ± 18.6 136.2 ± 21.4 0.33
Hemoglobin (g/%) 13.5 ± 1.4 11.3 ± 0.35 11.1 ± 0.9 0.76
Fasting blood glucose (mg/dL) 128 ± 51.4 124.9 ± 45.6 119.6 ± 55.4 0.65
Total cholesterol (mg/dL) 198.2 ± 49.3 199.7 ± 47.1 197.2 ± 51.2 0.82
LDL-cholesterol(mg/dL) 122.4 ± 38.8 123.9 ± 40.9 121.4 ± 37.9 0.77
Triglycerides (mg/dL) 164.5 ± 99.5 160.3 ± 97.0 167.3 ± 102 0.75
Serum Sodium (mEq/L) 139.4 ± 3.3 138.9 ± 3.5 139.7 ± 3.2 0.26
Echocardiogram: LA 43.1 ± 7.8 42.5 ± 6.1 43.6 ± 8.9 0.50
DDLV 63.5 ± 12.6 61.7 ± 8.2 64.7 ± 14.9 0.30
EF 37.8 ± 7.9 39.0 ± 6.8 37.0 ± 8.5 0.30
Creatinine (mg/dL) 1.3 ± 0.8 1.4 ± 1 1.3 ± 0.6 0.35
GFR 61.7 ± 22.9 61.4 ± 21.5 61.9 ± 24.1 0.90
Chronic kidney disease (41) 49.4% (14) 42.4% (27) 54% 0.05
Where: CHF = Chronic heart failure; BMI = Body mass index (kg/m2); SBP = Systolic blood pressure (mmHg); LA = left atrium (mm), DDLV = 
diastolic diameter of the left ventricle (mm); EF = ejection fraction (%). Data expressed as mean ± Standard deviation or number (n) and 
percentages (%). GFR = glomerular filtration rate (ml/min/1.73 m2).Page 4 of 7
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with CKD from the analysis [36].
In our study, it was observed that CKD (GFR <60 mL/min/
1.73 m2) present in stages B and C of CHF was associated
with 100% and 64.7% of the CV outcomes, respectively.
These results provide new information regarding the "nat-
ural" course of systolic CHF in its early stages, and if con-
firmed in studies with greater number of patients, they can
define renal function staging as a major tool to identify
risk factors for adverse outcomes in patients with less
severe CHF.
The unfavorable impact of CKD in the evolution of CHF
stages B and C imposes a better understanding of the rea-
sons for such an adverse association. In CHF, low cardiac
output, neurohumoral stimulation, aggressive use of diu-
retics, treatment with renin-angiotensin-aldosterone sys-
tem blockers, anemia, and comorbidities, such as
hypertension and diabetes mellitus, can contribute to the
reduction of GFR, and the observed functional deficit
merely reflects the severity of CHF in the baseline period
[34-37]. However, it is important to highlight that our
study only included outpatients already on optimized
treatment for CHF. Furthermore, we did not observe sta-
tistical differences in the frequency of diabetes and hemo-
globin levels in patients with CHF, with and without
CKD, which eliminates the possibility of these parameters
as determinants of adverse outcomes. These findings rein-
force our proposal that CKD per se, due to its own risk fac-
tors (pro-inflammatory markers, vascular rigidity,
dyslipidemia, hyper-homocysteinemia, proteinuria, hyp-
Presents the cardiovascular outcomes related to the pres-ence or not of chr nic kidney diseas  (CKD) in pati nts with th  chro ic he t failure as whol  (CHFT), and after s atifi-cation by s ag s B (CHFB) and C (CHFC)Figure 1
Presents the cardiovascular outcomes related to the 
presence or not of chronic kidney disease (CKD) in 
patients with the chronic heart failure as whole 
(CHFT), and after stratification by stages B (CHFB) 
and C (CHFC).
Table 2: Baseline characteristics of CHF stratified by stages and presence or not of CKD.
Patients with CKD Patients without CKD
Variables Total Stage B Stage C p Total Stage B Stage C p
N 41/83 42.4% (14) 54% (27) 0.05 42/83 45.23% (19) 54,76% (23) 0,45
Age (years) 66.9 ± 11.3 65.5 ± 12.4 67.6 ± 10.7 0.57 58.5 ± 11.6 56.6 ± 10 60 ± 12,7 0,34
Females (23) 56% (3) 33.3% (12) 66.7% 0.73 (18) 42,8% (10) 52,6% (8) 36,6% 0,24
Arterial hypertension (40) 97.6% (14) 100% (26) 98% 0.46 (39) 97,6% (17) 89,5% (22) 95,6% 0,42
DM2 (19) 46.3% (7) 50% (12) 44.5% 0.73 (22) 52,4% (11) 57,9% (11) 50,3% 0,21
Sedentarism (31) 75.6% (9) 64,3% (22) 81.5% 0.22 (26) 61,9% (9) 47,4% (17) 75,8% 0,07
Smoking (3) 7.3% 0 (20) 7.4% 0.30 (10) 23,8% (6) 31,6% (4) 17,4% 0,23
Ischemic cardiopathy (25) 61% (11) 78.6% (14) 51.8% 0.096 (25) 59,5% (12) 63,2% (13) 59,3% 0,45
BMI 28.2 ± 6.3 27.5 ± 6.9 29.3 ± 6 0.50 31,8 ± 8,8 29,6 ± 5,6 33,5 ± 10,5 0,15
Obesity (14) 34.1% (3) 21.4% (11) 40.7% 0.21 (19) 45,2% (7) 38,8% (12) 53,8% 0,24
SBP 134.1 ± 19.9 135 ± 22.4 133.7 ± 19 0.84 134,8 ± 20,8 129,5 ± 15,4 139,1 ± 23,9 0,14
Hemoglobin (g/%) 13.2 ± 1.6 13 ± 1.9 13.3 ± 1.4 0.62 13,7 ± 1,2 14 ± 1,5 13,4 ± 0,8 0,75
Blood Glucose* 114.4 ± 40.2 115.7 ± 37.7 113.6 ± 42 0.87 128 ± 59,1 131,6 ± 50,5 125 ± 66,4 0,72
Total cholesterol* 200.4 ± 49.5 207 ± 45.5 197 ± 52 0.54 197,9 ± 49,2 194,3 ± 48,7 200,9 ± 50,5 0,67
LDL-cholesterol* 128.7 ± 44.5 132.5 ± 46.7 126.6 ± 44.1 0.69 165,5 ± 40,3 117,3 ± 35,6 118,4 ± 28,3 0,91
Triglycerides* 162.5 ± 94.7 164.7 ± 93.7 161.4 ± 97 0.91 167,5 ± 103 157,1 ± 101,8 176 ± 105,5 0,56
Echocardiogram: LA 42.5 ± 7.7 41.8 ± 6.1 42.8 ± 8.5 0.69 43,8 ± 6,12 43 ± 6,3 43,1 ± 12,6 0,98
DDLV 60.9 ± 7.5 60.5 ± 6.4 61.1 ± 8.1 0.83 66,5 ± 9,3 62,7 ± 9,5 69 ± 19,6 0,23
FE 36.4 ± 8 38.4 ± 6.8 35.4 ± 8.4 0.26 39,2 ± 7,6 39,5 ± 6,9 38,9 ± 8,3 0,79
Creatinine * 1.7 ± 0.1 1.9 ± 1.5 1.5 ± 0.5 0.25 0,9 ± 0,2 0,9 ± 0,2 0,8 ± 0,2 0,02
GFR 42.8 ± 12 41.7 ± 15.1 43.2 ± 10.3 0.71 79,9 ± 14,3 75,9 ± 11,5 83,3 ± 15,7 0,09
Where: CHF = Chronic heart failure; DM2 = type 2 diabetes mellitus; BMI = Body mass index kg/m2; SBP = Systolic blood pressure, mmHg; LA = 
left atrium (mm); DDLV = diastolic diameter of the left ventricle (mm); EF = ejection fraction (%); GFR = glomerular filtration rate, ml/min/1.73 m2. 
* = mg/dL. Data expressed as mean ± standard deviation or number (n) and percentages (%).Page 5 of 7
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phosphorus), is an important determinant of the
observed increase in CV outcomes [37]. In an attempt to
better evaluate the unfavorable impact of CKD in the evo-
lution of CHF, we utilized a multivariate analysis to test
the hypothesis that renal dysfunction is an independent
determinant of poor prognoses, or merely a complication
of CHF. We adjusted for other covariables, such as CKD in
the baseline period, stage C of CHF, ejection fraction, ele-
vated LDL-cholesterol levels, sedentarism, and serum
sodium; and despite these adjustments, the concomitance
of CKD increased 3.6 times the occurrence of CV events.
This finding reinforces our hypothesis that CKD, inde-
pendently of the presence of other known risk factors,
contributes to the higher occurrence of death and hospi-
talization for cardiac causes in the early stages of CHF.
It is important to recognize the limitations of our study.
Renal function was evaluated by the GRF estimated from
creatinine, and not by the use of methods considered to
be the gold standard, such as inulin clearance [27]. In
addition, we chose to exclusively utilize the functional
component of the definition of CKD, in other words, GFR
<60 mL/min/1.73 m2; however, previous studies have
demonstrated that it is below this level of renal function
that the risk of mortality increases for all causes of CHF
[12,34]. Albuminuria, the main marker of structural renal
injury, another component of the definition of CKD, is
fundamental in patients with GF >60 ml/min/1, 73 m2,
and was not determined in this study since its occurrence
could be mitigated by the use of optimized angiotensin-
converting enzyme inhibitors, AT1 blockers, and aldoster-
one antagonists, thereby inducing false negative diag-
noses [37]. Additionally, our patients were selected from
an outpatient clinic attended mainly by hypertensive, dia-
betic, and obese patients, and thus, the cohort did not
entirely reflect the different etiologies of CHF, but, of
course, the most prevalent.
Clinical implications
CKD, a recognizable common risk factor for adverse out-
comes in more severe forms of CHF, is also frequent in
patients in the early stages of the disease. Our results cor-
roborate with the proposal for using GFR, mainly when it
is <60 mL/min/1.73 m2, as a strong prognostic risk factor
for adverse CV outcomes in CHF, also in patients with less
advanced heart failure. These findings suggest that clinical
physicians, particularly cardiologists, should incorporate
the serial estimation of GFR in order to optimize the
results of treatment in CHF. Future studies could elucidate
the determinants of the decrease in GFR in CHF stages B
and C, and whether or not preservation of renal function
will associate with an improved outcome of the cardiac
disease.
Conclusion
In the cohort studied, composed predominantly of hyper-
tensive, diabetic, and obese patients, CKD was common
and associated with an increased frequency of cardiovas-
cular outcomes. These findings should be confirmed in
studies with larger number of patients and greater diver-
sity of causes of left ventricular dysfunction, in order to
better understand the impact of renal function in the
course of CHF, and to stimulate the development of new
therapeutic strategies, aiming to reduce the rates of hospi-
talization and mortality, secondary to cardiovascular dis-
eases.
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Table 3: Univariate and multivariate analysis of the determinants of cardiovascular outcomes in patients with chronic heart failure
Univariate analysis Multivariate analysis
Variables Risk CI95% p value Risk CI95% p valor
Chronic kidney disease 2.891 1.052-7.949 0.04 3.641 1.045-12.679 0,042
Stage C of Cardiac heart failure 2.885 0.944-8.816 0.06 2.974 0.785-11.269 0,109
Ejection fraction (%) 0.910 0.854-0.970 0.004 0.925 0.862-0.942 0,03
LDL-cholesterol abnormal 0.354 0.120-1.044 0.06 0.417 0.109-1.593 0,201
Sedentarism 3.830 1.021-1.395 0.04 2.012 0.462-8.775 0,352
Sodium 0.825 0.694-0.981 0.03 0.807 0.862-0.992 0,03
Where: LDL-cholesterol abnormal = serum levels greater than 100 mg/dL.Page 6 of 7
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